Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Dysfunction Clear all
Completed Phase 2 Interventional Results available

The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction

NCT02554253
View directory record Official record
Conditions
Cognitive Disorders, Delirium, Acute Kidney Injury
Interventions
Ketamine, Propofol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
75 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Jul 23, 2026, 3:01 AM EDT
Recruiting Phase 3 Interventional

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

NCT05422534
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
CoQ10, Placebo, HB-HIIT, Observational
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 23, 2026, 3:01 AM EDT
Terminated Phase 1 Interventional

Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

NCT00818701
View directory record Official record
Conditions
Congestive Heart Failure, Renal Dysfunction
Interventions
low dose Nesiritide, nesiritide, Sildenafil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

NCT03422653
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
57
States / cities
Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Jul 23, 2026, 3:01 AM EDT
Withdrawn Phase 4 Interventional

Kidney Allograft Dysfunction Without Reversible Causes

NCT01492894
View directory record Official record
Conditions
Kidney Graft Dysfunction
Interventions
Cyclosporins/Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 3 Interventional Results available

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

NCT02251431
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions
BYDUREON, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 23, 2026, 3:01 AM EDT
Completed No phase listed Observational

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

NCT05611905
View directory record Official record
Conditions
Renal Excretion, Bacterial Infections, Inflammatory Disease, Oncologic Disease
Interventions
11C-para-aminobenzoic acid PET/CT, Probenecid
Combination Product · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Not applicable Interventional Results available

Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients

NCT00692419
View directory record Official record
Conditions
End Stage Renal Disease, Sexual Dysfunction, Physiological, Pain, Depression
Interventions
Symptom management nurse intervention, Feedback intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Jul 23, 2026, 3:01 AM EDT
Withdrawn Early Phase 1 Interventional

Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent

NCT05640115
View directory record Official record
Conditions
Cancer, Urinary Obstruction, Malignancy, Urinary Dysfunction, Ureter Obstruction, Ureter Injury
Interventions
Ureteral Stent, Percutaneous Nephrostomy Tube Placement
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

NCT01970176
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 23, 2026, 3:01 AM EDT
Not listed No phase listed Observational

Genetic Predictors of Renal Dysfunction Following Heart Transplantation

NCT01686191
View directory record Official record
Conditions
Heart Transplantation, Chronic Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 23, 2026, 3:01 AM EDT
Terminated No phase listed Observational

Sexual Function in Male Renal Transplant Patients

NCT00271830
View directory record Official record
Conditions
Renal Transplant Recipients
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 65 Years · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Jul 23, 2026, 3:01 AM EDT
Withdrawn Phase 1 Interventional

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

NCT06138327
View directory record Official record
Conditions
Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions
BMN 255, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jul 23, 2026, 3:01 AM EDT
Recruiting Phase 2 Interventional

Improving Coronary Vascular Health in Women

NCT06843902
View directory record Official record
Conditions
HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
Interventions
Health Education, Subspecialty clinic referral
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 23, 2026, 3:01 AM EDT
Withdrawn Phase 2 Interventional

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

NCT00878761
View directory record Official record
Conditions
Chronic Allograft Dysfunction
Interventions
STX-100
Biological
Lead sponsor
Stromedix, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 2 Interventional Results available

Trial of Oral Glutamine on Mitochondrial Function in CKD

NCT02838979
View directory record Official record
Conditions
Cardiovascular Disease, Sarcopenia, Endothelial Dysfunction, Muscle Mitochondrial Function, Kidney Disease
Interventions
First Intervention (14 days), Washout (3 weeks), Second Intervention (14 days)
Dietary Supplement · Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 2 Interventional Results available

Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease

NCT03223883
View directory record Official record
Conditions
Chronic Kidney Diseases, Cognitive Decline
Interventions
Curcumin, Placebo
Drug · Other
Lead sponsor
Diana Jalal
Other
Eligibility
45 Years to 74 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 2 Interventional

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

NCT00119691
View directory record Official record
Conditions
Congestive Heart Failure, Renal Insufficiency
Interventions
Nesiritide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 3 Interventional

Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure

NCT00170183
View directory record Official record
Conditions
Kidney Diseases, Congestive Heart Failure, Cardiomyopathy
Interventions
Nesiritide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2009 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

NCT01678794
View directory record Official record
Conditions
Cardiorenal Syndrome (CRS)
Interventions
Candesartan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

NCT01131845
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Renal Dysfunction
Interventions
UT-15C SR (treprostinil diethanolamine)
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 1 Interventional

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

NCT01444872
View directory record Official record
Conditions
Heart Failure, Kidney Disease
Interventions
TRV120027, Normal Saline
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2012 · Synced Jul 23, 2026, 3:01 AM EDT
Completed Phase 1 Interventional

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction

NCT00001298
View directory record Official record
Conditions
Kidney Diseases
Interventions
carboxypeptidase-G2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 3:01 AM EDT
Terminated Phase 4 Interventional

Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

NCT01277497
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sevelamer carbonate, Calcium acetate
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Jul 23, 2026, 3:01 AM EDT